tirzepatide weight loss in 3 months vs. 6 months on 3-Month Tirzepatide Update: Side Effects

The SURMOUNT-1 trial reported average reductions of up to 22% with tirzepatide over 72 weeks

MOTS-c regulates T-cell differentiation and activation (e.g., upregulation of Treg cells) in an mechanistic target of rapamycin complex 1 (mTORC1)-dependent manner and prevents pancreatic infiltration of autoreactive T-cells in non-obese diabetic (NOD) mice

Nadeau, MD , a board-certified endocrinologist

National trends in use of sodium-glucose cotransporter-2 inhibitors and glucagon-like peptide-1 receptor agonists by cardiologists and other specialties, 2015 to 2020

Keep up with these visits to make sure the treatment is safe and working well

If you are breastfeeding or plan to breastfeed, consult your doctor before starting Ozempic